Company Spotlight – SonoThera
SonoThera’s novel technology could unleash new genetic medicines with expanded patient access.
Now Available: Spotlight on Stilla Technologies Remi Dangla, PhD – CEO. Click here to read.
SonoThera’s novel technology could unleash new genetic medicines with expanded patient access.
Developing protein therapies is a numbers game. For every one molecule that safely and effectively treats a specific condition, billions of alternatives need to be sifted through to find it. This painstakingly slow and iterative process can take months or even years.
DELFI Diagnostics is developing a new generation of liquid biopsies that could advance these applications. Built on a new method called fragmentomics and amplified by machine learning, DELFI’s approach is already showing promise, providing early detection for lung, liver and other cancers, and could provide essential insights to inform precision medicine.
Diagnostic tests are vital, but the current system can be challenging. Blood draw sites are often inconvenient, and patients can wait days for results. In addition, people testing for sexually transmitted diseases (STDs), and other potentially sensitive conditions, may opt-out over privacy concerns. Sherlock Biosciences is working to address these issues by changing how people access diagnostics.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.